OncoImmune

OncoImmune is a clinical-stage biopharmaceutical company dedicated to the discovery and development of biologics for the treatment of cancer and autoimmune diseases. It has completed a Phase II clinical trial of CD24Fc for the prophylactic treatment of acute graft-versus-host disease (GvHD) in leukemia patients undergoing hematopoietic stem cell transplantation and is preparing to conduct a pivotal indication trial.